Last reviewed · How we verify
NCT03271372: ADAM
Adjuvant Avelumab in Merkel Cell Cancer
Phase 3 trial testing Avelumab in Stage III Merkel Cell Carcinoma AJCC v8 in 101 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2026
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | Phase 3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 101 |
| Start date | 19 December 2017 |
| Primary completion | 30 April 2026 |
| Estimated completion | 18 February 2029 |
| Sites | 9 locations across United States |
Drugs / interventions tested
- Avelumab (avelumab) — full drug profile →
- Peripheral Blood Collection
- Placebo
Conditions studied
- Stage III Merkel Cell Carcinoma AJCC v8 — all drugs for Stage III Merkel Cell Carcinoma AJCC v8 →
- Stage IIIB Merkel Cell Carcinoma AJCC v8 — all drugs for Stage IIIB Merkel Cell Carcinoma AJCC v8 →
- Stage IIIA Merkel Cell Carcinoma AJCC v8 — all drugs for Stage IIIA Merkel Cell Carcinoma AJCC v8 →
Sponsor
University of Washington
Who can join
18 and older, any sex, with Stage III Merkel Cell Carcinoma AJCC v8 or Stage IIIB Merkel Cell Carcinoma AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, et al · · 2019 · cited 279× · PMID 30726175 · DOI 10.1200/jco.18.01896 -
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.
Harms PW, Harms KL, Moore PS, DeCaprio JA, et al · · 2018 · cited 234× · PMID 30287935 · DOI 10.1038/s41571-018-0103-2 -
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP, Bhatia S, Brohl AS, Hamid O, et al · · 2020 · cited 123× · PMID 32414862 · DOI 10.1136/jitc-2020-000674 -
Non-Melanoma Skin Cancers: Biological and Clinical Features.
Cives M, Mannavola F, Lospalluti L, Sergi MC, et al · · 2020 · cited 120× · PMID 32751327 · DOI 10.3390/ijms21155394 -
Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
Colunga A, Pulliam T, Nghiem P. · · 2018 · cited 71× · PMID 29217527 · DOI 10.1158/1078-0432.ccr-17-0439 -
Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ, Emerick KS, Kaufman HL, Miller DM. · · 2021 · cited 64× · PMID 34448958 · DOI 10.1007/s11912-021-01120-z -
Product review: avelumab, an anti-PD-L1 antibody.
Collins JM, Gulley JL. · · 2019 · cited 62× · PMID 30481100 · DOI 10.1080/21645515.2018.1551671 -
Merkel Cell Carcinoma: An Update and Immunotherapy.
Uchi H. · · 2018 · cited 37× · PMID 29560342 · DOI 10.3389/fonc.2018.00048
Verify or expand the search:
- PubMed search for NCT03271372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Avelumab
Trials testing the same drug.
- NCT06939036 — Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) · Phase 1, PHASE2 · terminated
- NCT05687721 — Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer · Phase 1, PHASE2 · withdrawn
- NCT06518564 — Avelumab and M1774 in ARID1A-mutated Endometrial Cancer · Phase 2 · recruiting
- NCT06424717 — Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L · Phase 2 · withdrawn
- NCT06302426 — Trial of INI-4001 in Patients With Advanced Solid Tumours · Phase 1 · recruiting
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03271372 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03271372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing